Disulfiram-Cu inhibits the proliferation of breast cancer stem cells and potentiates the cytotoxic effects of paclitaxel, likely through a combined mechanism of ROS generation and NF-κB pathway suppression. Here, NFKB1 is linked to breast cancer.